Hemobahn Stent-Grafts for Treatment of Femoropopliteal Arterial Obstructions: Midterm Results of a Prospective Trial

Outcomes following treatment of femoropopliteal in‐stent restenosis: A single center experience

“…Unfortunately, stent grafts can restenose at the edges where intimal injury is not covered completely by graft material. This pattern of restenosis, in which the main body of the graft is free of restenosis and the edges restenose, appears to be characteristic of stent grafts [14][15][16]. Saxon et al [15], over a 4-year period of follow-up, reported that edge restenosis was present in up to 13.6% of 87 limbs treated with the Viabahn (W.L.…”

ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)

“…Investigational randomized trials suggest that endovascular brachytherapy may reduce restenosis rates of PTA and stenting in the femoral-popliteal arteries (469)(470)(471)(472)(473). Techniques to be investigated in randomized trials in the peripheral circulation include fabric-covered stents (474,475) and drug-coated stents (476,477).…”

Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease

“…The restenosis rates for this stent graft are somewhat mixed [19][20][21]. However, results for complex disease in studies utilizing antiplatelet therapy where the lesions were fully dilated and covered by the stent graft and when the lesions had favorable characteristics (good inflow, good outflow, mild to moderate calcification), the 1-year restenosis rates appear to average less than 20% [22][23][24][25][26][27]. Even more impressive the 2 and 3-year patencies appear to chal-lenge the results of femoropopliteal bypass utilizing PTFE grafts [28,29].…”